Lappaconitine hydrobromide has attracted much attention because of its unique pharmacological effects. It is mainly used in clinic for its strong analgesic effect. It is widely used in late cancer analgesia and surgery analgesia. At present, morphine and pethidine are the most effective analgesic drugs, but they are prone to adverse reactions such as addiction, drug resistance and constipation; Lappaconitine hydrobromide has significant analgesic, anti-inflammatory, detumescence, cooling, antipyretic and local anesthetic effects. Its analgesic intensity is 7 times that of aminopyrine and is equivalent to that of pethidine. Because of its strong analgesic and immunomodulatory effects, it was selected as a mild / moderate cancer pain analgesic for cancer three-step analgesic therapy. It can be used as an adjunct to chemotherapy for mild / moderate cancer pain and cancer patients. It can also cooperate with morphine to improve its analgesic effect and reduce the dosage and adverse reactions.

    A large number of clinical studies have also proved that Lappaconitine hydrobromide has a good effect whether administered through epidural or intravenous routes, or in combination with local anesthetics, opioids and used alone. For example, compound fentanyl is used in the operation of stomach, gallbladder, spleen and colon. Compound butorphanol was used for postoperative intravenous analgesia in gynecology, laparoscopic ovarian cyst removal, compound tramadol was used for postoperative analgesia in colon and cervical cancer, and only used for postoperative analgesia in abdominal and biliary surgery; In addition to these, Lappaconitine hydrobromide can also be used for induced abortion cesarean section analgesia, banded spore neuralgia, epidural injection postoperative analgesia, urethral syndrome, soft tissue injury, knee inertia arthritis, sciatica, etc. Lappaconitine hydrobromide is not easy to produce drug resistance and addiction, and is easy to take orally. It has a huge application space in cancer pain relief. Studies have proved that for patients with clinical perioperative analgesia, injecting different doses of lappaconitine hydrobromide into the epidural space for analgesic treatment is more effective than intravenous injection, intramuscular injection and oral administration, and there are no adverse reactions and complications related to delayed respiratory depression and potential addiction of epidural injection. Therefore, Lappaconitine hydrobromide can be used for clinical epidural postoperative analgesia instead of morphine.

    However, with the increase of its clinical application, it has been reported that it can cause severe allergic reaction, induce purpura, cause salivary gland swelling, ear mastoid process mass, tinnitus, hearing loss and other ototoxicity, cause restlessness, cyanosis of mouth, lips and tongue, cause mental depression, shallow coma, arrhythmia, conduction block, ventricular fibrillation, and even cause small and respiratory arrest. It is worth paying attention to in clinical application.

    With the further research,Lappaconitine hydrobromideMany pharmacological effects of lappaconitine hydrobromide have been found, the scope of analgesia has been expanding, and its clinical application prospect is promising. However, in clinical application, it is necessary to pay close attention to the adverse reactions and precautions of lappaconitine hydrobromide, so as to make its clinical use safe, effective and reasonable.